Physician profile
Eric Zhang
NPI 1982282760
$2,399.93
in general payments reported to CMS, 2019-2025
9 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $122 · 2024: $588 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $625.53 | 2024-2025 | Rocklatan, Simbrinza, Rhopressa |
| Sun Pharmaceutical Industries INC. | $497.68 | 2024-2025 | |
| Dompe US, INC. | $485.05 | 2023-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $459.11 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Janssen Biotech, INC. | $145.64 | 2025 | Tremfya |
| Amgen INC. | $90.50 | 2025 | Tepezza |
| Thea Pharma INC. | $46.48 | 2024-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $36.28 | 2024 | Xdemvy |
| Abb Con-Cise Optical Group LLC | $13.66 | 2024 | Contact Lens, Spectacle Lenses |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.